Last reviewed · How we verify

Live attenuated rotavirus vaccine

GlaxoSmithKline · Phase 2 active Biologic

Live attenuated rotavirus vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development.

At a glance

Generic nameLive attenuated rotavirus vaccine
SponsorGlaxoSmithKline
ModalityBiologic
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Live attenuated rotavirus vaccine

What is Live attenuated rotavirus vaccine?

Live attenuated rotavirus vaccine is a Biologic drug developed by GlaxoSmithKline.

Who makes Live attenuated rotavirus vaccine?

Live attenuated rotavirus vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is Live attenuated rotavirus vaccine in?

Live attenuated rotavirus vaccine is in Phase 2.

Related